FDA senior official reverses staff decision to approve Replimune's skin cancer therapy

Newly released FDA documents show that Asha Das, director of the biologics center's clinical evaluation office, overrode the internal review team's rejection to grant accelerated approval to Replimune's melanoma drug Tudriqev in early August. The move represents a rare instance of a senior regulator overturning a staff recommendation. The approval covers a treatment for melanoma, a form of skin cancer.

The decision, made public through recently released FDA documents, marks an uncommon departure from standard regulatory procedure. Asha Das, who leads the clinical evaluation office within the biologics center, chose to grant accelerated approval for Replimune's Tudriqev despite the internal review team's earlier rejection. The reversal occurred in early August, positioning the therapy as a new option for patients with melanoma.

Accelerated approval pathways are typically reserved for treatments addressing serious conditions with unmet medical needs. Melanoma remains one of the more aggressive forms of skin cancer, and regulatory decisions affecting its treatment options carry significant weight. The rarity of a senior official overturning staff-level recommendations adds notable dimension to this approval, though the specific clinical data behind the reversal was not detailed in the available materials.